Zeteletinib

Zeteletinib
Identifiers
	IUPAC name 2-[6-(6,7-dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide;
CAS Number	2216753-97-6 [UNII];
PubChem CID	134391533;
ChemSpider	115007145;
UNII	EP0P7SHM0U;
ChEMBL	ChEMBL5095497;
Chemical and physical data
Formula	C25H23F3N4O4
Molar mass	500.478 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C1=NOC(=C1)NC(=O)CC2=CN=C(C=C2)C3=CN=C4C=C(C(=CC4=C3)OC)OC)C(F)(F)F;
	InChI InChI=1S/C25H23F3N4O4/c1-24(2,25(26,27)28)21-11-23(36-32-21)31-22(33)7-14-5-6-17(29-12-14)16-8-15-9-19(34-3)20(35-4)10-18(15)30-13-16/h5-6,8-13H,7H2,1-4H3,(H,31,33); Key:KOLQINCWMXQEOF-UHFFFAOYSA-N;

Zeteletinib (BOS-172738, DS-5010) is an experimental anticancer medication which acts as a RET inhibitor.^[1]^[2]

References

^ Vodopivec DM, Hu MI (2022). "RET kinase inhibitors for RET-altered thyroid cancers". Therapeutic Advances in Medical Oncology. 14: 17588359221101691. doi:10.1177/17588359221101691. PMC 9218446. PMID 35756966.
^ Gou Q, Gan X, Li L, Gou Q, Zhang T (December 2022). "Precious Gene: The Application of RET-Altered Inhibitors". Molecules (Basel, Switzerland). 27 (24): 8839. doi:10.3390/molecules27248839. PMC 9784389. PMID 36557971.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.